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THE ONCOGENIC MAP KINASE SIGNALING PATHWAY MODULATES MHC-I 
SURFACE EXPRESSION IN MELANOMA 
 
Sherille Denae Bradley, B.S. 
Advisory Professor: Gregory A. Lizee, Ph.D. 
The mitogen-activated protein kinase (MAPK) pathway is a cascade of serine-
threonine kinases involved in cell growth, proliferation, and apoptosis; it is one of the most 
well-known pathways associated with melanoma progression. The MAPK pathway is 
constitutively activated in melanomas due to mutations in the signaling components, 
particularly the proto-oncogene BRAF 
V600E  
 that accounts for (40-50%) of these cases. 
Metastatic melanoma is one of the deadliest and most aggressive forms of cancer, with a 3-
year survival rate of less than 15%. Immunotherapies that utilize cytotoxic T lymphocytes 
(CTLs) have proven to be very effective at inducing regressions of large, bulky tumors, and 
in improving melanoma patient survival. Two MAPK targeted inhibitors, vemurafenib and 
dabrafenib, have produced positive results in clinical trials thus far, but they are not without 
limitations. Recent studies have shown that oncogene activation in tumor cells can affect the 
level of expression of major histocompatibility complex I molecules (MHC-I) on the cell 
surface, and potentially allow melanoma cells to escape immune system surveillance.
 
MHC-
I molecules expressed by tumor cells are the crucial targets recognized by CTLs to kill 
tumor cells; thus, strategies to improve MHC-I antigen presentation to T-cells is very likely 
to improve the efficacy of current immunotherapies. In DCs and other hematopoietic cell 
types the rapid internalization and recycling of MHC-I through endocytic compartments has 
been characterized as a cytoplasmic tail dependent process. The MHC-I cytoplasmic tail 
    
 
v 
 
possesses two conserved phosphorylation sites, a tyrosine (Y320) and serine (S335).  It is 
known that MAPK pathway activation can induce a phosphorylation signaling cascade in 
tumor cells, but the mechanism behind the regulation of MHC-I internalization and 
modulation has yet to be identified in tumor cells.  
In our study we show that both BRAF and MEK inhibitors increase MHC-I surface 
expression in BRAF 
V600E
 melanoma mutant cell lines. Additional studies have shown that 
the level of MHC-I surface expression directly affects CTL recognition and cytokine release. 
We also reveal a novel potential mechanism for MAPK pathway regulation of MHC-I 
through the highly conserved serine encoded by exon 7 of the MHC-I cytoplasmic tail. 
These studies suggest that the mechanism behind MAPK regulation of MHC-I is through 
serine phosphorylation and inhibition of this process allows for a longer surface half-life of 
MHC-I molecules leading to better CTL responses. Ultimately, we have shed light on MHC-
I surface expression, trafficking, internalization and antigen presentation in melanoma. 
Knowledge gained through this study could aid in the development of cancer treatment 
strategies whereby MAPK pathway inhibition is used to augment the effectiveness of CTL-
based immunotherapies. Furthermore, these types of therapeutic approaches may be 
generalizable to other tumor types that also demonstrate constitutive MAPK pathway 
activation.                                
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1.1 MELANOMA  
Melanoma is a dangerous form of skin cancer that often develops from melanocytes 
exposed to UV radiation and the body’s inability to repair the damaged cells. Unrepaired 
DNA damage leads to mutations within the melanocytes that can transform the cells into 
cancerous cells. Melanoma is known to metastasize to other parts of the body.  Metastatic 
melanoma is one of the deadliest and most aggressive forms of cancer, with a 3-year 
survival rate of less than 15% [1].  Immunotherapeutic approaches that utilize cytotoxic T 
lymphocytes (CTLs) have proven to be very effective at inducing regressions of large, bulky 
tumors, and in improving melanoma patient survival [2].  
Proto-oncogenes are genes that are known to a have high potential to induce cancer. 
The most relevant proto-oncogene in metastatic melanoma is BRAF kinase, a component of 
the mitogen-activated protein kinase (MAPK) pathway. Constitutive activation of this 
pathway by a characteristic BRAF mutation (V600E) contributes to the fatality of metastatic 
melanoma by inducing many uncontrolled cellular changes, including cell proliferation and 
immune suppression. Current oncogene- targeted approaches have helped to extend the life 
of many patients, but they have generally not proven to be effective in extending the lives of 
patients beyond 6 or 7 months. With a better understanding of how the MAPK pathway is 
affecting the immune response, we can develop strategies to improve the efficacy of current 
melanoma therapies.   
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1.2 MAP KINASE SIGNALING PATHWAY 
Protein kinases are enzymes that phosphorylate proteins by covalently attaching 
phosphate groups to the side chain of serine/threonine or tyrosine residues [3], and regulate 
the activity, localization, and function of proteins involved in many cellular processes. 
Kinases most commonly are involved in signal transduction and cell cycle regulation. There 
are many of distinct protein kinases, and in recent years over 100 different kinases have 
been discovered [4].  Based on their substrate specificity, kinases fall within certain family 
groupings. Kinases can be characterized as serine/threonine or tyrosine kinases. 
This study specifically focuses on serine/threonine kinases, which play a major role 
in  the control of the cell cycle and in receptor-mediated signaling pathways [5]. Mitogen-
activated protein kinases (MAPK) are a group of highly conserved serine/threonine protein 
kinases, whose function and regulation have been conserved throughout evolution, from 
simple organisms like brewer’s yeast to highly complex organisms, such as mammals [3].  
Years of research have been invested to characterize the protein kinases involved in this 
pathway. Despite the extensive characterization of the signaling cascade, there are still many 
unknowns surrounding the downstream effects of this pathway on gene expression. Because 
this signaling pathway is often deregulated in tumor cells, a more complete understanding of 
this signaling pathway could lead to improvements of targeted-therapies for cancer patients. 
The MAPK pathway specifically consists of the Ras/Raf/MEK/ERK (extracellular-
signal-regulated kinase) pathway, a series of protein kinases that regulate the expression of 
proteins involved in cellular growth and survival (Figure 1.1) [6,7]. The MAPK pathway 
responds to the binding of cytokines, growth factors, hormones, and other stimulating 
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factors that bind to receptors on the cell surface [6,7,8]. Because of their important roles in 
cellular functions , MAPK components have been studied extensively in human diseases. 
MAPKs are responsible for catalyzing the addition and removal of phosphates to 
substrate proteins; as such, they act as an on and off switch to control the activity of other 
proteins [3]. The process of phosphorylation is regulated by the feedback loop system of 
MAPKs and protein phosphatases working in a reciprocal matter to change the behavior of 
cells in response to extracellular signals. There are three central, sequentially-activated 
kinases that make up the signaling cascade in the MAPK pathway, these three kinases are 
known as MAPKKKs (ex. BRAF), MAPK kinase (ex. MEK 1/2), and MAPK (ex. ERK 
1/2). These kinases are all serine/threonine kinases that are activated through 
phosphorylation and their interaction with GTP proteins of the Ras/Rho family in response 
to extracellular stimuli [5,9].  
Our study will focus on the ERK 1/2 pathway, one of major MAPK signaling 
pathways [10]. The ERK 1/2 pathway was the first pathway identified and currently the best 
described MAPK pathway [10]. The ERK cascade typically responds to extracellular growth 
signals. In response to stimuli, the Ras-guanosine diphosphate (GDP) is exchanged with 
Ras-guanosine triphosphate (GTP) which binds to Raf, leading to the activation of kinases in 
the pathway. The binding of RasGTP to Raf family members relays a signal to the MAPK 
signal cascade; once the MAPKs are activated, they phosphorylate serine/threonine residues 
on their target proteins [10].   
There are three Raf proteins expressed by human cells: RAF-1, ARAF, and BRAF 
[7]. The focus of this study is the raf protein BRAF. When BRAF is activated, it 
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phosphorylates the kinases MEK 1/2, which in turn activates downstream phosphorylation 
in the MAPK pathway. In normal cells, the activation of the MAPK pathway is quickly 
reversed and the MAPK phosphorylation cascade is switched off [11]. One of the major 
hallmarks of cancer is the ability of cancer cells to sustain their proliferation signals. 
Mutations that induce the constitutive activation of MAPK pathway components can induce 
uncontrolled cellular proliferation, which will be further outlined in the following section. 
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            Figure 1.1 Schematic representation of the MAP kinase pathway. MAP kinase 
pathway schematic representation showing sequential kinase phosphorylation and 
activation. [12] C. Fremin, S. Meloche, From basic research to clinical development 
of MEK1/2 inhibitors for cancer therapy, J Hematol Oncol 3 (2010) 8.  (Reprinted 
with permission of the authors). 
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1.3 MAP KINASE PATHWAY SIGNALING BY ONCOGENES 
Proto-oncogenes are genes that are activated by changes in normal DNA such as 
mutations, translocations, or gene amplifications resulting in increased function for that 
individual gene [13,14]. These genetic events lead to its constitutive activation and 
dominance over the normal functioning gene. The pathogenesis of malignant tumors can be 
largely attributed to the constitutive activation of oncogenes within the tumor cell. 
Activating point mutations can lead to the uncontrolled cell proliferation, as described for 
the RAS and RAF oncogenes [15,16]. RAS and RAF are components of the MAPK kinase 
signaling cascade, and mutations to these proteins RAS or RAF have been identified in 
multiple forms cancer with varying degrees of prevalence. Such mutations have been 
identified in melanomas, colorectal cancers, lung cancers, sarcomas, liver, and breast 
cancers [11].  
In melanoma, the MAPK pathway predominantly activating contains mutations in 
the NRAS and BRAF proto-oncogenes. NRAS mutations account for 15-20% and BRAF 
mutations account for 40-50% of cases of constitutive activation of this pathway [11,13,17]. 
Over 90% of BRAF mutations consists of a single substitution of thymine with adenine at 
nucleotide 1799; this change leads to valine (V) being substituted by glutamate (E) at codon 
600, and the mutation is referred to as BRAFV600E [18].  Immunosuppression has recently 
been linked to the activation of the MAPK signaling pathway thru BRAF (V600E) mutations.  
For example, the oncogenic MAPK pathway upregulates the inflammatory cytokines IL-1 
α/β in melanoma cells [19]. Tumor-associated fibroblasts (TAFs) in turn respond to IL-1 
upregulation by producing PD-1 ligands, and COX-2, leading to an ongoing suppression of 
CTLs preventing them from performing their function [20]. In addition to the suppression of 
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the immune response, BRAF mutations are also associated with a poorer prognosis for these 
patients. 
The bridge between CTL-mediated immunotherapy and other therapies that target 
the BRAF (V600E) mutation has grown tremendously, with a wide array of new developments 
in many areas, including combination therapies. As discussed below, there is growing 
evidence that such combinations may act in synergy to improve response rates for melanoma 
patients. 
1.4 BRAF-TARGETED THERAPY AND CLINICAL RESULTS 
Each year in the U.S.,  76,000 new cases of melanoma are diagnosed, and 9000 
people died from the disease in 2012 [21]. The aggressive nature of melanoma, once it 
spreads, has been a major issue for the treatment of patients. Early diagnosed cases of 
melanoma can be surgically removed, but not all tumors are resectable. In advanced stages 
of melanoma, chemotherapy is not very effective due to the rapid development of resistance. 
Furthermore, metastatic melanoma proliferates at a rapid pace and can disseminate to almost 
any part of the body [21]. Prognosis for metastatic melanoma patients is poor, with only 
10% of  patients living to 5 years post diagnosis, and the median survival being less than a 
year [22].  
Many different therapeutic approaches have been taken to treat metastatic melanoma 
patients. The FDA-approved chemotherapy for melanoma treatment Dacarbazine induces 
objective responses in only 10-15% of patients, but has no benefits for on progression-free 
or overall survival of patients. The use of drugs that activate CTLs, like interleukin-2, yield 
higher rates of complete responses, but do not result in a higher overall survival rate [23]. In 
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recent years, the focus has turned to the use of oncogene-targeted therapies to provide a 
more effective treatment for melanoma sufferers. BRAF-targeted inhibitors have become the 
new standard of treatment for aggressive melanomas, but issues with tumor resistance have 
plagued clinicians and researchers since the development of these drugs. The need to gain 
more knowledge, and better understand how resistance in the MAP kinase pathway drives 
tumor progression remains paramount to the development of better treatments for 
melanoma. 
Dozens of small-molecule inhibitors have been developed over the past couple of 
decades to target specific mutated oncogenic proteins within the MAP-kinase pathway 
(Table 1.1) and clinical trials have been designed to test these inhibitors. In 2002, the first 
BRAF mutations were reported. At that time, Sorafenib was the best available kinase 
inhibitor. Sorafenib can inhibit a broad spectrum of cellular targets, such as VEGFR-2, 
PDGFR, and C-KIT, FLT-3, CRAF, wild-type BRAF or BRAFV600E [24].  Sorafenib was 
able to inhibit BRAF but in order to work for MEK and ERK deactivation, high micromolar 
concentrations were required that led to off-target effects and toxicities [25]. Therefore, a 
need for more selective oncogene-targeted inhibitors led to the development of BRAF 
inhibitors that specifically target mutated BRAF (V600E). 
BRAF (V600E) -targeted therapy is one of the most significant therapeutic advances 
for the treatment for melanoma in many years. PLX-4032 (Vemurafenib) was the first 
BRAF inhibitor approved by the US Food and Drug Administration (FDA) for treatment of 
patients with metastatic melanoma or unresectable tumors [26]. GSK2118436 (Dabrafenib) 
is another BRAF inhibitor that also has been approved by the FDA. Because both  inhibitors 
are specific for the mutated BRAF,  they are classified as type I BRAF kinase inhibitors 
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[21]. Although both inhibitors can act on WT BRAF at higher concentrations, they have 
both induced significant beneficial effects on patients in clinical trials thus far [25].    
The first human trials using vemurafenib and dabrafenib were performed in 
metastatic melanoma patients [27]. In the vemurafenib phase I clinical trial, 32 patients 
enrolled and 81% of the enrolled patients possessed a BRAF (V00E) mutation. Each patient 
received the maximum dosage of 960mg twice a day, and both  complete and partial 
responses were recorded [28]. Phase II and phase III trials confirmed the results from the 
phase I trial, and showed about 48% of the patients responded to treatment [29]. Similar 
response rates were observed in a parallel dabrafenib phase I trial. In the first dabrafenib 
trial, patient tumors were measured at baseline and two weeks after the start of BRAF 
inhibitor treatment.  The level of ERK phosphorylation was also analyzed at each point. In 
patients that responded,  80% showed phospho-ERK inhibition and some patients had 
inhibition levels as high as 90-95% [25]. Patient response rates varied from 2 months up to 
over 2 years of progression-free survival, but the median duration of response was roughly 7 
months. 
By contrast, the MEK inhibitor GSK1120212 (Trametinib) is an example of a 
selective small-molecule MEK 1/2 inhibitor [22]. In a phase III trial, a total of 322 patients 
with metastatic melanoma were randomly treated with either trametinib or one of two 
chemotherapy drugs. The overall goal of the trial was to get all patients to progression-free 
survival; if this did not occur for patients treated with chemotherapy, they had the option to 
switch to trametinib treatment. The median progression-free survival of trametinib-treated 
patients was 4.8 months and for the chemo-treated patients it was 1.5 months. At 6 months, 
the overall survival was 81% for trametinib patients and 67% in the chemo treated group. At 
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the end of the trial, 22% of patients in the trametinib-treated group had objective responses 
compared to only 8% of the chemotherapy treated group [22 ,25].  
With all three MAP kinase inhibitors, toxicity and side effects can be a threat to 
progression-free survival. Both vemurafenib and dabrafenib caused rashes and  the 
development of squamous-cell carcinomas in some patients that was attributed to the 
appearance of HRAS mutations [30]. The carcinoma lesions that appeared in some patients 
were largely managed by excision [30,31].  As for patients treated with trametinib, the side 
effects experienced were more severe, ranging from rashes to diarrhea, and peripheral 
edema [32] [33].  
Table 1.1 Small Molecule Inhibitors Used for Targeting MAPK Pathway.  
 
BRAF-targeted therapy has provided many patients with increased progression free-
survival time, but the development of resistance has been a major problem associated with 
treatment. The MAP kinase pathway can contain multiple mutations that activate ERK, and 
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some patients develop alternative mutations (i.e. NRAS) that are not specifically targeted by 
BRAF inhibitors. In clinical trials, it was determined that at least two-thirds of patients 
developed restored ERK phosphorylation despite prior inhibition [25]. The activation of 
ERK signaling took place as early as two weeks into treatment, and in some cases the 
amount of ERK phosphorylation was increased in comparison to baseline levels of phosho-
ERK [25]. Resistance mechanisms include NRAS mutations, alternatively-spliced BRAF 
variants, amplification of BRAF and downstream changes to MEK activation [34].  
To combat resistance, new potential targets for the MAP kinase pathway have been 
identified. Different MEK inhibitors could possibly decrease or prevent the occurrence of 
pERK re-emergence post BRAF inhibitor treatment. MEK targets that are downstream of 
RAF may be good potential targets. In addition the Phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3K), Protein kinase B (AKT), mechanistic target of rapamycin (mTOR) (better 
known as the PI3K/AKT/mTOR) pathway is involved in melanoma signal transduction; 
phosphatase and tension homolog (PTEN), a suppressor gene in the pathway, suggest 
potential additional targets to stop the reactivation of downstream ERK. Pre-clinical data 
support the possibility that these pathways are relevant to the pathogenesis of BRAF-mutant 
melanoma and could possibly be used by tumor cells as a means for immune evasion [35] 
[36].   
An alternative approach to treating resistance in metastatic melanoma patients is the 
use of combination therapy. For example, in addition to combining targeted agents like 
BRAFi and MEKi, more recently the combination of targeted agents with checkpoint 
inhibitors, such as ipilimumab, a monoclonal antibody that blocks the co-inhibitory 
molecule cytotoxic t-lymphocyte associated protein 4 (CTLA-4), has gained more traction 
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clinically [37]. Ipilimumuab was approved by the FDA in 2011 and is currently undergoing 
clinical trials for use in combination with immunotherapies for melanoma patients. In 
addition to the use of ipilimumuab, newly developed monoclonal antibodies that block 
programmed cell death 1 (PD-1) and its ligand, CD274 (PD-L1) are also being tested 
currently. As always, many questions arise as to how these combinations will affect patient 
tumor progression, survival and overall health. Regardless, the future of BRAF-targeted 
therapy and immunotherapy as means of treatment for metastatic melanoma patients looks 
promising, as outlined further below. 
1.5 CTL-MEDIATED IMMUNOTHERAPY 
Cancer immunotherapies have grown exponentially in recent years; where 
chemotherapies have failed, they have proven to be a respectable alternative treatment. The 
adaptive immune response relies heavily on immune effector cells known as cytotoxic t-
lymphocytes (CTLs). Also referred to as CD8+ T-cells, CTLs are known to be major players 
in the regression of tumors. CD8+ T-cells recognize major histocompatibility complex class 
I (MHC-I) molecules that display peptide antigens on all cell types in the body. In addition 
to distinguishing self-antigens and non-self-antigens, effector CD8+ cells can be primed to 
target antigens that are located on different types of cancers, known as tumor associated 
antigens (TAAs) [38].  Lymphocytes that infiltrate into the stroma of cancer nodules are 
referred to as Tumor infiltrating lymphocytes (TILs) [39,40]. TILs provided the first 
evidence that the immune system can recognize tumor antigens [41,42]. In 1988, Wolfel et 
al. showed that target structures located on human leukocyte antigens (HLA) displayed on 
tumor cells could induce the killing of these cells by CTLs [42]. The target structures 
identified were later described as the first tumor antigens recognized by T-cells [43]. 
    
 
14 
 
Intracellular proteins are comprised of poly-peptide chains, and within a cell they are split 
into shorter peptides that can be presented at the cell surface when loaded onto MHC-I 
molecules. Peptides can range from  8 to 12 amino-acids that are derived from specific cell-
associated proteins, and are recognized by the T-cell receptor of CTLs [44].  Peptides can 
only bind to specific MHC alleles that possess particular amino acid binding motif 
preferences [44,45].  The targeting of TAAs through various treatment methods has been the 
foundation of cancer immunotherapy. 
Several different T-cell based immunotherapies have been developed to treat 
melanoma. For example, the cytokine interleukin-2 (IL-2) is responsible for the growth, 
proliferation, and differentiation of T-cells to become effector cells. IL-2 is produced by T-
cells following T-cell recognition of a foreign pathogen or a tumor antigen. IL-2 as 
monotherapy or combinations of IL-2 and TILs were some of the first successful  T-cell 
mediated immunotherapies developed for the treatment of cancers [39]. Cancer vaccines can 
also be used to prime anti-tumor T-cell responses. Melanoma researchers have identified 
proteins that are expressed with high frequency amongst most melanoma patients, Melan-
A/MART-1 and gp-100. Because these proteins are expressed only in melanocytes and 
melanoma cells, they are considered good TAA candidates [44,46]. Certain cancer vaccines 
utilize peptides derived from these proteins to induce an adaptive immune response.  Tumor 
antigens combined with an adjuvant can be used to prime the immune system to develop 
more antigen specific T-cells and more potent anti-tumor immunity. However, the use of 
vaccines for activating T-cells is not without complications, under certain circumstances 
peptide-specific T-cells can become tolerized and become unresponsive [47]. This can range 
from issues with the dose of peptide or the adjuvant used during immunization. An over-
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stimulation of the immune response can also lead to exhaustion of memory T-cells within 
the body.  
An alternative to peptide vaccines involves using them in conjunction with 
professional antigen presenting cells (APCs) that have been loaded with peptides and 
injected into patients. The most potent APCs for inducing T-cell activation are dendritic 
cells (DCs); T-cell receptors interact with MHC-I on DCs, leading to T-cell priming. DCs  
normally internalize protein antigens from cells, process the antigens and then travel to the 
lymph nodes to present the peptides to T-cells [48]. APCs also have the unique ability to 
present both endogenously derived peptides through MHC-I and exogenously derived 
peptides on MHC-II complexes. In a process known as cross presentation, APCs can present 
also exogenously-derived peptides on recycled MHC-I molecules [49]. The discovery that 
DCs normally uptake antigens and present them to activate T-cell responses led to the 
rationale that peptide-loaded DCs would be good candidates for initiating an anti-tumor 
response [49,50,51].  Although most DC-based cancer vaccines have shown promise for 
inducing anti-tumor T-cells in peripheral blood, induction of clinical responses has been 
comparatively rare. 
1.6 ROLE OF MHC-I IN T-CELL MEDIATED IMMUNE RESPONSES 
MHC-I is a central focus of immune response. Peptides derived from many types of 
cells including self, non-self, pathogen, and tumor-derived are displayed by these molecules 
to effector T-cells by all nucleated cells of the body. MHC-I molecules are able to present 
endogenously-derived peptides, but in professional antigen presenting cells (APCs), such as 
dendritic cells (DCs), MHC-I molecules are also able to present exogenously-derived 
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peptides. Mature MHC-I complexes are assembled in the endoplasmic reticulum (ER); they 
are heterodimers assembled from a polymorphic heavy chain, and a light chain called β2- 
microglobulin (β2m) and antigenic peptide [52,53]. Since they display these peptides at the 
cell surface, and MHC-I molecules play an important role in antigen presentation. 
Proteasomes degrade cytoplasmic proteins into smaller peptides, which are transported into 
the ER by the transporter associated with antigen presentation (TAP) and are loaded in to the 
peptide binding grooves of the MHC-I molecules. The MHC-I binding groove 
accommodates peptides 8 to 12 amino acids in length [52]. In the ER, MHC-I molecules are 
stabilized by chaperone proteins such as calreticulin [54]; in addition, the molecule Tapasin 
interacts with TAP to assist in the delivery of peptides to MHC-I molecules. When a peptide 
is successfully bound to MHC-I and β2- microglobulin as a trimolecular complex, it exits 
the ER via the secretory pathway and travels to the cell surface in vesicles for presentation.  
Human MHC-I molecules are referred to as human leukocyte antigens (HLA). The 
three classical MHC-I genes are HLA-A, HLA-B, and HLA-C, and each HLA type can 
recognize and bind uniquely to certain peptides because of the molecular properties of the 
their peptide binding grooves [55]. HLA-A and HLA-B are expressed in higher levels in the 
human cells than HLA-C. The extremely high level of MHC-I Polymorphism results in 
different peptide-binding grooves that recognize and bind characteristic peptide sequences, 
allowing for each individual to present a wide and distinct array of peptides.  
Each HLA molecule loaded with peptide is expressed on the cell surface to present 
peptides to CD8+ T-cells, this can induce clonal expansion of effector of T-cells, target cell 
killing or cytokine release, depending on the APC and T-cell differentiation state. T-cells 
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contain a T-cell receptor that binds to MHC-I; when this occurs; many more stabilizing 
receptors bind to one another from each cell thus allowing the T-cell to stay in close contact 
to release effector molecules. Granzyme B and perforin are two common molecules released 
by CD8+ cytotoxic T-cells to induce target cell death. Granzyme B is a serine protease 
secreted by T-cells (and other non-cytotoxic cells like mast cells and basophils) that is 
involved in inducing inflammatory cytokine release [56]. Perforin is a pore-forming protein 
that enters target cells; once inside, it triggers an increase of intracellular calcium and 
eventually leads to the apoptosis of target cells [54]. 
MHC-I molecules possess both an extracellular region that contains the peptide-
binding region, a transmembrane domain, and a cytoplasmic tail.  The MHC-I cytoplasmic 
tail plays a role in antigen presentation, but it has not been extensively studied.  Studies have 
shown that the tail is involved in intracellular trafficking and antigen-presentation in APCs, 
but little is known about its role in tumor cells. The MHC-I cytoplasmic tail is 35 amino 
acids in length and is encoded by three exons: 6, 7, and 8. This region is highly conserved 
throughout species [52] [57]; Exon 6 and 7 each contain potential tyrosine and serine 
phosphorylation sites, respectively [53]. Recent research has revealed that a natural splice 
variant occurs in some organisms (not in human beings); whereby exon 7-encoding amino 
acids are deleted from cytoplasmic tail region. Previously published work from our lab 
revealed that DCs transduced with this exon 7-deleted variant had a longer cell surface half-
life and this contributed to better recognition and killing by T-cells [57].  
Furthermore, previous studies showed that tyrosine-320 encoded by exon 6 is crucial 
for MHC-I endolysosomal trafficking in DCs and contributes to the ability of MHC-I to 
acquire and present exogenously derived peptides [53]. MHC-I molecules utilized by DCs 
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are extremely important for activating T-cell mediated adaptive immune responses. The fact 
that the MHC-I cytoplasmic tail plays a role in trafficking in DCs may also help shed light 
on the role of the cytoplasmic tail in antigen presentation by tumor cells or other nucleated 
cells, which will be discussed further below.  
1.7 MODULATION OF MHC-I BY PATHOGENS AND ONCOGENES 
Since MHC-I displays fragments of intracellular proteins on the cell surface, it is 
essential for immune surveillance by T-cells. The MHC-I molecule is expressed by all 
nucleated cells; any cell can be infected by a viral pathogen, or subjected to mutations that 
may lead to cancer. Peptides derived from mutated proteins are presented to CD8+ T-cells, 
which in turn can induce an adaptive immune response. Interestingly, pathogens and cancer 
cells evolve ways to avoid being detected by the immune system in order to downgrade the 
immune response as much as possible. Since MHC-I molecules are so fundamental to the 
immune response, they are often the targets of these mechanisms of immune evasion.  
Defects in MHC-I mediated antigen presentation renders cells unrecognizable to T-cells and 
provide an important advantage to both pathogens and tumor cells. 
Several different components of the antigen presentation machinery (APM) can be 
lost or targeted, which can have implications for MHC-I mediated antigen processing, 
loading, and presentation. For example, defects in the proteasome that cleaves proteins into 
peptides have been identified in some tumor cell types. In addition, downregulation of 
subunits of the proteasome such as β, ΜΒ1, and Z have been characterized in carcinomas, 
colorectal, ovarian and bladder cancers [58,59,60]. In melanoma cells, downregulation of 
other inducible subunits (LMP2, 7, and 10) related to the proteasome have been 
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characterized [61,62]. Without proteasomes, cells can’t produce the peptides required for 
MHC-I surface expression and T-cell killing of target cells. Other APM components 
commonly lost in tumor cells are the TAP1 and TAP2 genes. Tumor cells have been found 
to downregulate these peptide transporters, which are important for loading peptides onto 
MHC-I molecules [58]. In addition, viruses such as HCMV can express proteins that directly 
inhibit TAP 1 and 2.  
The MHC-I cytoplasmic tail is also a target of viruses within tumor cells. Human 
immunodeficiency virus (HIV) is one of the most deadly diseases that can affect humans, 
partially due to its ability to escape the immune system. HIV encodes a molecule called Nef, 
which targets the MHC-I molecule at the cytoplasmic tail, thus disrupting the trafficking and 
intracellular localization of MHC-I [63].  Nef was shown to associate with the cytoplasmic 
tail in humans, in a manner that was dependent on the tyrosine-320 residue encoded by exon 
6 [63].  When the cytoplasmic tyrosine of the HLA-A2 molecule was mutated, Nef lost the 
ability to downregulate the surface expression of MHC-I [64].  
Sometimes tumor cells can overexpress growth factor receptors, leading to the 
downregulation of MHC-I molecules as a mechanism of immune system escape. For 
example, expression of HER2 in breast cancer cells has been shown to inversely correlate 
with MHC-I expression. HER2 is a proto-oncogene and a member of the epidermal growth 
factor (EGFR) family of tyrosine kinases. A study conducted by Inoue et al. showed that the 
overexpression of  HER2 led to a downregulation in HLA-A2 molecules and less 
recognition by HER2-specific CTLs [65]. Interestingly, mutated HER2 overexpression is 
also linked to activation of the MAPK pathway [66].  
    
 
20 
 
Other oncogenic mutations have been shown to regulate the level of MHC-I on the 
cell surface. In particular, BRAF inhibitors (BRAFi) have been shown to induce an 
upregulation of MHC-I, melanoma differentiation antigens, and other immune system 
activators [19].  When  metastatic melanoma cells were treated with  BRAFi PLX 4720 
(vemurafenib) in conjunction with IFN-γ, nanomolar concentrations of vemurafenib 
enhanced MHC-I, MHC-II, and β2- microglobulin in Mel A375 cells after 24 hours [67]. 
This upregulation of MHC- I has also been seen in other melanoma studies. For example, 
MAP kinase pathway inhibition induced upregulation of MHC-I and melanoma antigens, 
MART-1, gp100, and trp-1/2 in multiple melanoma cell lines after 72 hours of drug 
treatment [68].  
Notably, BRAF inhibition has been shown in several studies to relieve immune 
suppression within the melanoma tumor microenvironment, leading to better CTL 
infiltration and function.  In vitro experiments have shown that BRAF inhibition can 
decrease the release of immunosuppressive cytokines such as, IL-1, IL-6 and IL-8 [19]. In 
vivo mouse studies have also shown that PLX4720 (BRAFi) can significantly increase 
tumor infiltration of adoptively transferred T-cells, and induce better antitumor activity 
through the inhibition of melanoma tumor cell production of vascular endothelial growth 
factor (VEGF) [69]. In addition, melanoma patient tissue samples examined after BRAFi 
treatment showed an increase in CD8+ T-cell infiltration and markers of T-cell cytotoxicity. 
This increase of CD8+ cells was attributed to a decrease in the immunosuppressive 
cytokines IL-6 and IL-8 [70]. 
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An increase in antigen presentation following MAP kinase pathway inhibition 
appears to be one outcome of BRAF inhibitor treatment, but it remains unclear how MHC-I 
expression is modulated by the MAP kinase pathway at the mechanistic level. This is 
important, since MHC-I upregulation following treatment by MAPK inhibitors should lead 
to better CTL recognition and killing of melanoma cells. How exactly is the MAP kinase 
pathway connected to MHC-I surface expression? A better understanding of how MAPK 
pathway and MHC-I are all connected may help shed light on a potentially important 
immune system evasion mechanism that tumor cells use.  The rationale behind this project is 
that MHC-I down regulation on the cell surface of melanoma cells, can be reversed by 
treatment with MAPK pathway inhibitors. This occurrence has been documented in 
melanoma [65,67,71]. Increases in MHC-I surface expression following inhibitor treatment 
suggest that the upregulation is regulated by MAPK signaling. Since the MAPK pathway 
induces a phosphorylation cascade, we explored the hypothesis that MHC-I cytoplasmic tail 
phosphorylation mediates this connection. A potential model for how this connection might 
be mediated is shown in Figure 1.3. 
1.8 AIMS OF PROJECT 
It is our central hypothesis that MAP kinase pathway activation upregulates MHC-I 
surface expression through altering phosphorylation of the MHC-I cytoplasmic tail. The 
goal of this project is to identify the mechanism behind the regulation of  MHC-I surface 
expression, which has yet to be identified in tumor cells [67].   
To determine the connection between the oncogenic MAPK pathway and the surface 
expression of MHC-I, we explored two aims:  
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AIM 1:    Assess the effects of MAPK pathway inhibitors on MHC-I surface expression in 
melanoma cells and their subsequent recognition by melanoma antigen specific T-cells.                                                 
• Aim 1.1.  Determine the effects of three different clinically used BRAF / MEK 
inhibitors on total MHC-I cell surface expression with a panel of human melanoma 
cells.  
 
• Aim 1.2 Determine the role of the MHC-I cytoplasmic tail in the MAP kinase 
pathway dependent modulation of MHC-I surface expression in melanoma cells.  
 
• Aim 1.3.  Determine if modulating the level of melanoma cell MHC-I surface 
expression through MAPK pathway inhibition improves CTL-mediated recognition 
and killing. 
 
AIM 2:  Identify the mechanism of modulation of MHC-I molecules by the oncogenic 
MAPK pathway.  
• Aim 2.1 Determine the steady state rate of internalization of MHC-I molecules in 
BRAF mutant melanoma cell lines. 
 
• Aim 2.2: Determine whether MAPK pathway inhibitors slow the rate of 
internalization of MHC-I molecules, and if the process is cytoplasmic tail dependent. 
 
This research is significant because MHC-I molecules are crucial targets recognized by 
CTLs to kill tumor cells; thus, strategies to improve MHC-I mediated antigen presentation to 
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CTLs are likely to increase the efficacy of current immunotherapies. Knowledge gained 
from these experiments can ultimately improve our understanding of how the MAPK 
pathway controls MHC-I surface expression, trafficking, internalization, and antigen 
presentation in melanoma. A better understanding of how oncogenic signaling pathways 
regulate MHC-I may allow for the development of novel cancer treatment strategies 
whereby different inhibitors targeting MHC-I downregulation can be used to augment the 
effectiveness of CTL-based immunotherapies. Furthermore, these types of therapeutic 
approaches may be generalizable to the many tumor types that demonstrate constitutive 
MAPK pathway activation. 
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Figure 1.3.  Potential role of MHC-I tail phosphorylation in controlling MHC-I trafficking in 
melanoma cells. Working model of possible mechanism of the MHC-I cytoplasmic phosphorylation 
before and after BRAF inhibition in melanoma cells. 
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CHAPTER II: 
MATERIALS AND METHODS 
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2.1 Cell Culture and Transduction 
Human melanoma cell lines expressing BRAFV600E mutations, Mel888 and WM793 
were transduced with HLA-A*0201 isoforms using lentiviral gene transfer vectors (Figure 
3.2 A). The human (hPGK) promoter was used to drive the expression of WT, ∆T, ∆S and 
∆Y HLA-A*0201 isoforms [57]. Transduced cells expressing similar levels of surface HLA-
A2 were isolated by cell sorting (Figure 3.2 B). Additionally, three untransduced human 
melanoma lines were utilized, two BRAF-WT cells HS294T, Mewo and Melanocytes. 
Mel888 lines were cultured in RPMI 1640 medium (GIBCO Grand Island, NY) containing 
10% fetal bovine serum (GIBCO), 10 IU/mL penicillin (Cellgrow Manassas, VA), 10 
µg/mL streptomycin (Cellgrow), Insulin-Transferrin-Seleum-A (GIBCO) and maintained at 
37°C in 5% CO2.   WM793, HS29T, and MeWo cells were grown in similar media without 
the addition of insulin. Melanocytes were cultured in HEMa media (Life Technologies). 
TILs were utilized in T-cell assay experiments. TIL were maintained in RPMI-1640 medium 
containing 10% fetal bovine serum, 10 IU/mL penicillin, 10ug/mL streptomycin and 
supplemented with 200 IU/mL of IL-2.  
2.2 Isolation and REP of TIL  
MART-1 CD8+ specific tumor infiltrating lymphocytes (TIL) obtained from infusion 
product (>98% MART-1 specific) were generously donated by Dr. Laszlo Radvanyi (M.D. 
Anderson Cancer Center Houston, TX).  To obtain TILs, melanoma tumor cells were 
resected from stage IV- melanoma patients. The tumors were cut into 3-5mm2 fragments.  
The fragments were placed in a 24 well plate with TIL culture media (TIL-CM) and 6000 
IU/ml interleukin-2 (IL-2) to grow TIL from the fragments. After 3 weeks in TIL-CM the 
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Pre-Rapid Expansion (pre-REP) TILs were transferred to T-25 flasks for rapid expansion. 
The REP was performed in upright T-25 flasks by activating 1.3 X 105  pre-REP TIL with 26 
X 106 allogenic, irradiated (5000cGy) PBMC feeder cells with 30ng/ml OKT3 (anti-CD3; 
Abbott Park, IL) in 1:1 mixture of TIL-CM and AIM -V (Invitorgen). TILs expanded from 
tumor fragments were harvested after 5 weeks and stained for CD8 expression and 
recognition of the HLA-A2 MART-1 peptide tetramer. TILs were designated as pre-REP 
and were re-stimulated with MART-1 peptide. The TILs were expanded for another 12 days 
and diluted as needed with AIM -V and IL-2 to keep the viable cell density in the range of 
1–2 × 106/ml. The post-REP TILs were isolated and washed in TIL-CM and rested for 3–6 
hrs. before re-stimulation. Expanded TILs were routinely stained for human T cell 
differentiation markers using fluorochrome-conjugated mAb recognizing CD3, CD4, CD8, 
CD27, CD28, CD57, and CD62L obtained from BD Biosciences (San Jose, CA) or 
eBiosciences (La Jolla, CA). TILs were stained with HLA-A2 MART-1 peptide 
(ELAGIGILTV) tetramer (Beckman Coulter, Fullerton, CA) to track changes in the MART-
1–specific CD8+ subpopulation. The stained cells were acquired by using a BD FACScanto 
II flow cytometry analyzer and FACSDiva software (BD Biosciences). Data were analyzed 
by FlowJo software (TreeStar, San Carlos, CA).  
2.3 MAPK Pathway Inhibitors 
BRAF V600E inhibitor GSK2118436 (Selleckchem), and MEK inhibitors 
GSK1120212 (Selleckchem), and AZD6244 (Selleckchem), were used to treat melanoma 
cells. Each MAPK pathway inhibitor was titrated for optimal concentration and incubation 
time (Figure 3.1B). Inhibitors were dissolved in DMSO and stored at -80 in aliquots. 
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2.4 Antibodies and Flow cytometric analyses 
Analysis of surface MHC-I expression on melanoma cell lines was carried out by 
standard flow cytometry methods. Anti-human HLA-A2-APC (BB7.2) , Anti-human HLA 
A,B,C-APC (w6/32),  Anti-human IFN-g-PE (B27),  Anti-human CD8-Pacific Blue (SK1), 
Alexa Flour 647 (IgG2b) Isotype control antibodies were obtained from the following 
(Biolegend San Diego, CA); Streptavidin-APC was obtained from (BD Biosciences) and 
HLA antibody A1,A36 –Biotin conjugated was obtained from (US biological). Transduced 
melanoma cell lines were cultured with BRAF inhibitor or MEK inhibitors and untreated 
control (RPMI only) for 3hrs. Cells were seeded at 1.0 X 106 cells in a 12 well plate.  Each 
inhibitor was diluted in 10mL of growth media to 100nM each and added to each well to a 
volume of 2mL and a final concentration of 50nM. After treatment melanoma cells were 
washed, and stained either with HLA-A2, HLA-A, B, C, or HLA-A1 molecules 
respectively, and analyzed using FACScantoII flow cytometer (BD Biosciences, Jose CA). 
For TILs intracellular antigens were stained using the fixation and permeabilization protocol 
from the BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit with BD 
GolgiPlug™ (BD biosciences San Jose CA). Stained cells were analyzed using a 
FACScanto II flow cytometer (BD Biosciences San Jose CA). Data was analyzed using 
Flowjo analysis software (Treestar Ashland OR). 
2.5 T-cell assays 
For all T-cell assays MART-1 CD8+ specific TILs obtained from infusion product 
(>98% MART-1 specific) were used.  Transduced WM793 cell lines were pulsed with 
titrated concentrations of MART-1 peptide, and co-cultured with effector MART-1 TILs at a 
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1:1 ratio (10,000 tumor: 10,000 effector cells) and  incubated at 37°C for 4hrs, following a 
3hr incubation with BRAF inhibitor (50nM). Transduced Mel888 cell lines were co-cultured 
with effector MART-1 TILs at a 1:1 ratio at 37°C for 4hrs, following a 3hr incubation with 
BRAF inhibitor. TILs were collected and cytokine IFN-γ production was measured by 
intracellular cytokine staining. TIL were incubated with melanoma cell lines for 4hrs in the 
presence of GolgiStop (BD Biosciences), washed, fixed, permeabilized, and stained using 
anti-mouse or anti-human IFN-γ conjugated to APC (BD Biosciences). The cells were 
incubated for 4 hours because GolgiStop is toxic to cells when in culture past 6 hours. 
Human T-cells were also stained a fluorescently labeled anti-human CD8 antibody 
conjugated to Pacific Blue (BD Biosciences). Antigen-specific intracellular IFN-γ 
production by CD8+ T-cells was then determined by flow cytometric analysis. 
 
2.6 Enzyme-linked immunosorbent assay 
ELISA’s were performed with WM793 and Mel888 transduced cell lines. Each cell 
line was seeded into 20,000 cells per well in 96 well plates. BRAF inhibitor (GSK2118436) 
was used to treat cells at concentration of 50nM per well for 3 hrs. Concurrently cells were 
also incubated without inhibitor for 3hrs in media as a control. Two hours into treatment 
WM793 cells were pulsed with MART-1 peptide for 1 hr., after an hour the cells were 
washed with PBS twice and re-suspended in media.  After 3 hours of inhibitor treatment 
MART-1 specific TILs were added to the media at various tumors to TIL ratios and 
incubated overnight. After  8hrs of incubation, the media was collected from each well and 
used to determine the amount of IFN-γ secreted from the TIL using the Ready Set GO! 
ELISA Human IFN-γ kit (eBiosciences). Plates were read using SpectraMax® M5/M5e 
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Multimode Plate Reader and program. Data was analyzed with the Excel spreadsheet 
program. 
2.7 Western Blotting 
BRAF WT cell lines HS294T and Mewo, BRAF mutant melanoma cells, WM793 
and Mel888 were incubated for three hours in BRAF and/or MEK inhibitor at 50nM and 
100nM concentrations. Cell lysates were prepared and protein content was normalized using 
the BCA method (Thermo-Fisher Rockford, IL).  Membranes were probed with antibodies 
against total MEK, P-MEK, total MAPK, P-MAPK (Cell signaling) and total ERK2 (Santa 
Cruz Biotechnology). Protein was analyzed using the Scientific Pierce Fast Western Blot Kit 
(Thermo-Fisher Rockford,IL). 
2.8 Internalization Assay  
Untransduced and HLA-A2 transduced Mel888, WM793 and Mewo cells were 
incubated in BRAF inhibitor (GSK2118436) for 3 hrs. in 6 well plates at 1.0 X 106 cells per 
well. To determine the effect of the BRAF inhibitor on internalization of MHC-I, drug was 
washed off the cells with PBS and the cells were re-suspended in drug-free media. Next, 
each plate was placed into 4 degree at different time points 0 minutes (point directly after 
drug removal), 30, 60, 90, and 180 minutes respectively to stop internalization. After the 
final time point was collected the cells were then washed and stained with HLA-A2 APC 
(Biolegend, San Diego, CA) antibody at 1:200 dilutions. Stained cells were analyzed using a 
FACScanto II flow cytometer (BD Biosciences San Jose CA). Data was analyzed using 
Flowjo analysis software (Treestar Ashland OR). 
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2.9 Confocal Microscopy 
All cells were seeded and plated in Ibidi 12-well chamber on microscope glass slides 
(Ibidi, Verona, WI). For internalization steady state assays all cells were cultured in RMPI 
1640  media (GIBCO Grand Island, NY) with 10% FBS (invitogen), 20mM HEPES 
(Invitrogen). Mel888 and WM793 cells were placed on ice to stop internalization and 
labeled with AF488 antibody (Biolegend) for 30 minutes. The cells were then incubated for 
0, 30, 60, and 180 minute time points. The cells were washed twice with PBS, and fixed 
with 4% PFA for 10 minutes.  At each time point the cells were taken out and fixed, after 
each sample was fixed the cells were then stained for surface MHC-I using goat anti mouse 
AF555 antibody (Biolegnd) for 30 minutes on ice. After the surface is stained the nucleus is 
then labeled with Hoechst for 10 at room temperature, then washed twice. The cells were 
then imaged using Leica SP2 confocal microscope with 63X oil lens and 1.4 N/A. 
To analyze internalization with or with BRAF inhibitor the cells were first labeled at 
14 degrees for 30 minutes with MHC-I antibody AF488 (Biolegend). The cells were washed 
twice with PBS. The cells were then treated with either 50nM of dabrafenib diluted in 
DMSO (Selleckchem) for 90 minutes or untreated control with only DMSO (invitogen). The 
time point 90 minutes was used because the cells become very unhealthy with repeated 
washings and treatment at later time points. After 90 minutes the cells were then washed, 
and fixed with 4% PFA for 10 minutes, and surface MHC-I was labeled with goat anti 
mouse AF555 (Biolegnd) at room temperature for 1 hour. After the surface was stained the 
nucleus was then labeled with Hoechst for 10 at room temperature, and the cells were 
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washed twice. The cells were then imaged using Leica SP2 confocal microscope with 63X 
oil lens and 1.4 N/A. 
2.10 Statistical analysis 
Graph Pad Prism 6 was used for graphing and statistical analysis. A student’s t- test was 
used to analyze the statistical significance of all flow data. A one-way ANOVA test was 
used to analyze confocal microscopy quantification data. A p-value less than or equal to 
0.05 was the cut-off to determine the significance of the statistics. 
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CHAPTER III: 
RESULTS 
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Overview 
MHC-I expression can be upregulated in BRAF mutant melanoma cells following 
MAPK pathway inhibition [67].  Our experiments sought to shed light on the mechanism 
behind the modulation of MHC-I expression and the specific role that the MHC-I 
cytoplasmic tail may play in this phenomenon. It is known that the tyrosine (Y320) encoded 
by exon 6 and amino acids encoded by exon 7 of the MHC-I cytoplasmic tail are involved in 
MHC-I trafficking [52,53]. Therefore, we hypothesized that phosphorylation of the tyrosine 
(Y320) or serine (S355) from exon 7 may be controlled by the oncogenic MAP kinase 
signaling pathway, thus affecting MHC-I intracellular trafficking.  In order to determine this, 
we examined BRAF mutant melanoma cell lines to further understand the modulation of 
MHC-I by the oncogenic MAP kinase pathway and to identify a possible mechanism behind 
regulation of MHC-I. 
3.1 Inhibition of the MAP kinase pathway increases HLA-A, B, C surface expression in 
BRAF mutant cell lines. 
 In previously published reports, the increase in MHC-I expression after MAP kinase 
pathway inhibition was observed after 24-72 hours of treatment. However, these late time 
points pointed to transcriptional upregulation of MHC-I, which was of concern in our study. 
We therefore wanted to focus on earlier time points,  less than 3 hours that may uncover  
post-transitional modifications as opposed to the effects of transcription factors that can take 
place within 24hrs of treatment [72].  
To determine an optimal time point for drug treatment to inhibit the MAP kinase 
pathway and to induce changes in MHC-I expression we tested the  BRAFi  at  times 0 
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minutes, 30 minutes, 60 minutes, and 180 minutes. We then performed flow cytometry 
analysis to determine the level of total MHC-I on the cell surface at each time point. The 
results in Fig.3.1A show that after 180 minutes of MAPK pathway inhibition, MHC-I is 
maximally upregulated on the cell surface in comparison to the untreated control. 
To determine the kinetics of blocking the BRAF signaling pathway, we evaluated the 
levels of MAPK phosphorylation as readout for MAPK pathway activation. Total ERK was 
used as a control for phospho-ERK. The results shown in Fig. 3.1B reveal that the level of 
ERK phosphorylation was substantially reduced after 3 hours of treatment using both a 
BRAF inhibitor (Dabrafenib) and a MEK inhibitor (Trametinab) for 3 hours at low 
concentrations (10nM), or  high concentrations (50nM), compared to vehicle (DMSO) 
treated cells. In addition, a BRAF WT control cell line, HS294T, showed no change in the 
level of phospho-ERK following treatment with the BRAF inhibitor (Dabrafenib.  These 
results confirmed that the MAPK signaling pathway was blocked at the drug concentrations 
and time points tested. 
Next we examined the effects of two clinically used MAPK pathway inhibitors, 
Dabrafenib, and Trametinab on the surface expression of total MHC-I molecules. We treated 
melanoma cells for 3 hours at a 50nM concentration and as a control, we used DMSO only 
(vehicle). The levels of MHC-I were observed by flow cytometry and mean fluorescence 
intensity (MFI) was measured to determine difference in total MHC-I expression in two 
BRAF mutant cells lines (Mel888 and WM793) and one BRAF WT line (HS294T) (Fig. 
3.1C).  The results show that MHC-I was upregulated in the BRAF mutant cells, while the 
level of MHC-I did not change in the BRAF WT line. These results ultimately show that the 
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oncogenic MAPK signaling pathway can affect the level of MHC-I surface expression in 
melanoma cells and that MAPK inhibition can reverse these effects.  
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Figure 3.1 Inhibition of the MAP kinase pathway increases HLA-A, B, C surface 
expression in BRAF mutant cell lines. (A) Mel888 and WM793 BRAF mutant cell lines 
were treated with DMSO (vehicle) or dabrafenib for 30 minutes and 3 hours later total 
surface HLA-A,B,C was stained with W6/32 antibody and cells were analyzed by Flow 
cytometry. Values represent the mean florescence intensity (MFI) (B) Cells were treated 
with vehicle (DMSO), 10uM, or 50uM of dabrafenib (BRAFi). Mel888 was also treated 
with Trametinib (MEKi) (indicated by *). Whole cell lysates were prepared and levels of 
phospho-ERK and total ERK were analyzed by immunoblotting. (C) Two BRAF mutant cell 
lines, Mel888 and WM793 and one BRAF WT cell line, HS294T were treated with DMSO 
(vehicle), dabrafenib(BRAFi) and trametinib (MEKi) for 3 hours. Following treatment the 
cells were stained with W6/32 antibody to measure HLA-A, B, C and analyzed by flow 
cytometry. Left panels show shifts of MHC-I as histograms, and the right panels show actual 
MFI of MHC-I in a bar graph format. These experiments were repeated at least four times to 
confirm results. (* indicates p < 0.05; NS: not significant). 
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Figure 3.1  
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3.2 Creation of cell lines expressing HLA-A2 cytoplasmic tail variants  
 To determine if the MHC-I cytoplasmic tail was involved in the modulation of 
MHC-I by the MAP kinase pathway, cell lines transduced with cytoplasmic tail mutations of 
HLA-A2 were made. The melanoma cell lines Mel888 and WM793 were selected for 
transduction because they lack the expression of endogenous HLA-A2, and also possess a 
targetable BRAF activating mutation (V600E).  Lentiviral vectors [57] were used to 
transduce the cell lines with WT HLA-A2;  ∆T-A2, containing a complete deletion of the 
cytoplasmic tail; ∆S, a point mutant that replaces the serine to an alanine at S335, and ∆Y,  
containing a similar point substitution to tyrosine(Fig 3.2 A). The transduced cells were then 
sorted, and immunoblotting was used to confirm that the correct HLA-A2 tail variant was 
present in each cell line (Fig 3.2 B).  Surface expression of HLA-A2 was checked by flow 
cytometry to ensure that the surface expression comparable was between all cell lines 
expressing the HLA-A2 variants (Fig 3.2 C).   
Following transduction of the BRAF mutant cells, we next wanted to determine if 
the inhibitors were able to successfully block the MAPK signaling pathway in the HLA-A2 
transduced cell lines. We evaluated the levels of MEK and ERK2 phosphorylation as 
readout for MAPK pathway activation in the WT-A2 and ∆T-A2 lines. Total ERK and MEK 
were also used as a control. The results in Fig. 3.2 D reveal that the levels of MAPK 
phosphorylation were significantly reduced after 3 hours of treatment with both the BRAF 
inhibitor (Dabrafenib) and the MEK inhibitor (Trametinab). The cells were treated with a 
low concentration (10nM), a high concentration (50nM), and a vehicle (DMSO). The results 
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also show that 50nM of drug was sufficient to block ERK and MEK phosphorylation within 
3 hours. 
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Figure 3.2. Creation of cell lines expressing HLA-A2 cytoplasmic tail variants (A and 
B) Amino acid sequences of the cytoplasmic domains of  WT, ∆T, ∆S, and ∆Y  HLA-
A*0201. Tyrosine 320 and Serine 335 phosphorylation sites are depicted in red.  Bottom, 
Lentiviral vectors used to transduce BRAF mutant melanoma cells. The human 
phosphoglycerate kinase (hPGK) promoter was used to drive the expression of WT, ∆T, ∆S, 
and ∆Y isoforms of HLA-A*0201. (C) Mel888 and WM793 melanoma cells were 
transduced to express comparable levels of surface HLA-A*0201, as determined by HLA-
A2-specific western blot and mAb staining and flow cytometry. (D) Cells were treated with 
vehicle untreated (DMSO), 10uM, or 50uM of dabrafenib (BRAFi) and trametinib (MEKi). 
Whole cell lysates were prepared and levels of phospho-MAPK and ERK were analyzed by 
immunoblotting.   
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Figure 3.2  
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3.3 The MAPK pathway regulates the surface expression of MHC-I in a 
cytoplasmic tail-dependent matter. 
To determine if the MAP kinase pathway modulation of MHC-I was dependent on 
the cytoplasmic tail, we analyzed HLA-A2 WT and ∆T-A2 transduced BRAF mutant cell 
lines Mel888 and WM793. Each were treated with DMSO (vehicle), dabrafenib, or 
trametinib for 3 hours. Following treatment, the cells were stained with HLA-A2 specific 
antibody (BB7.2) and analyzed by flow cytometry to determine the levels of HLA-A2 on the 
cell surface following treatment (Fig.  3.3A). The results revealed that there was an 
upregulation in the HLA-A2 transduced WT cell line, while the tailless cell line showed no 
change in MHC-I surface expression. Therefore, indicating that the MHC-I cytoplasmic tail 
must be involved the upregulation of MHC-I on the cell surface following BRAF inhibitor 
treatment. 
In these experiments, we also analyzed HLA-A1 as an endogenous control in all of 
our HLA-A2 transduced cell lines.  We used HLA-A1 because it has a WT cytoplasmic tail 
and should there be subjected to surface expression changes after inhibitor treatment. We 
examined the WT and tailless HLA-A2 cell lines; each were treated with 50nM of 
dabrafenib or trametinib for 3 hours, and following treatment the cells were stained with an 
HLA-A1 specific antibody to observe the surface expression level post treatment of drug. As 
expected, the results revealed that HLA-A1 increased in both the WT-A2 and tailless HLA-
A2 cell lines, similar to the total MHC-I increase shown in Fig.  3.3B.   
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Figure 3.3 The MAPK pathway regulates the surface expression of MHC-I in a 
cytoplasmic tail dependent matter. 
(A) HLA-A2 transduced Mel888 and WM793 cells were treated with DMSO (vehicle), 
dabrafenib (BRAFi), or trametinib (MEKi) for 3 hours. Following treatment, the cells were 
stained with HLA-A2 antibody (BB7.2) and analyzed by flow cytometry. Left panels show 
MHC-I surface expression as histograms and the right panels show MFI of MHC-I as a bar 
graph. (B) HLA-A1 was measured by flow cytometry in Mel888 and WM793 cells 
transduced with WT-A2 and ∆T-A2 following treatment with 50uM BRAF or MEK inhibitor 
for 3 hours. Left panels show changes of MHC-I surface expression as histograms and the 
right panels show MFI of MHC-I in a bar graph format. These experiments were repeated at 
least four times with similar results. (* indicates p < 0.05; NS: not significant). 
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Figure 3.3 
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3.4 Highly conserved serine-335 of the MHC-I cytoplasmic tail mediates modulation of 
MHC-I surface expression by the MAPK pathway.  
Since our results revealed a connection between the MHC-I cytoplasmic tail and 
MAP kinase pathway inhibition, we next wanted to determine which regions of the MHC-I 
tail might mediate this connection. To determine which part of the MHC-I cytoplasmic tail 
modulated MHC-I expression, we next analyzed HLA-A2 cytoplasmic tail point mutants ∆Y 
and ∆S. Point mutants of the tyrosine (320) and Serine (S335) were used because they are 
both putative sites of phosphorylation on the cytoplasmic tail. If the tyrosine or serine are 
key sites involved in MHC-I modulation, we might be able to see that mutating these sites 
will abrogate modulation of surface expression of HLA-A2 in the untreated vs the drug- 
treated cell lines. To determine if the MAP kinase pathway modulation of MHC-I was 
dependent upon the two conserved phosphorylation sites, we assessed ∆Y and ∆S HLA-A2 
expression in transduced BRAF mutant cell lines Mel888 and WM793. Each cell line was 
treated with DMSO (vehicle), dabrafenib, or trametinib for 3 hours. Following treatment, the 
cells were stained with HLA-A2 specific antibody (BB7.2) and analyzed by flow cytometry 
to determine the levels of HLA-A2 on the cell surface following treatment (Fig.  3.4A).  
 In a similar manner to the previous experiment, we analyzed at endogenous HLA-
A1 as a control in the ∆Y and ∆S cell lines. Each was treated with 50nM of dabrafenib and 
trametinib for 3 hours; following treatment, the cells were stained with an HLA-A1 specific 
antibody to observe the surface expression level post treatment. The results revealed that 
HLA-A1 expression increased in both the cell lines similar to the total WT MHC-I as 
expected (Fig. 3.4B).   
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The results revealed that the ∆Y-A2 molecule behaved in a similar matter to the WT-
A2 molecule, while ∆S-A2 acted similarly to ∆T-A2. These results suggested that the MHC-
I cytoplasmic tail modulation is serine-dependent and not tyrosine-dependent. These results 
are the first to not only connect the cytoplasmic tail to MAP kinase signaling pathway  but 
also to implicate a particular conserved phosphorylation site to the surface expression of 
MHC-I in tumor cells. 
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Figure 3.4 Highly conserved serine-335 of the MHC-I cytoplasmic tail mediates 
modulation of MHC-I surface expression by the MAPK pathway.  
 (A) Two BRAF mutant cell lines, Mel888 and WM793 were transduced to express HLA-A2 
with point mutations to Y320 (∆Y-A2) or S335 (∆S-A2). Each cell line was treated with 
DMSO (vehicle), dabrafenib, or trametinib for 3 hours. Following treatment, the cells were 
stained with BB7.2 HLA-A2 antibody and analyzed by flow cytometry. Left panels show 
surface expression of MHC-I depicted as histograms and the right panels show MFI of 
MHC-I expression in a bar graph format. (B) HLA-A1 was measured by flow cytometry in 
two BRAF mutant cell transduced with ∆Y-A2 or ∆S-A2 following treatment with 50uM 
BRAF or MEK inhibitor for 3 hours. Left panels show MHC-I expression as histograms and 
the right panels show actual MFI of MHC-I as a bar graph. These experiments were repeated 
at least four times with similar results. (* indicates p < 0.05; NS: not significant). 
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Figure 3.4  
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3.5 BRAF inhibitor treatment of BRAF mutant cell lines increases subsequent T-cell 
recognition and IFN-γ secretion. 
 
To assess the significance of inhibitor-mediated MHC-I upregulation, we next measured 
the effect of these changes on T cell recognition and activation. Thus, we sought to 
determine the T-cell response to each transduced HLA-A2 cell line following BRAF 
treatment. In the first set of experiments, we analyzed CD8+ MART-1 specific TIL (> 90% 
tetramer recognition) of Mel888 cells which naturally express MART-1 [73].  WM793 cells 
pulsed with MART-1 peptide were used as targets because they do not express MART-1 
protein naturally. Mel888 cells transduced with HLA-A2 variants were treated with the 
BRAF inhibitor dabrafenib for 3 hours, the cells were washed, and T-cells were added at a 
1:1 ratio in triplicate. Golgi block was added to the media to block the secretion of IFN-
γ and the cells were co-incubated with T-cells for 8 hours. T-cells were collected and 
washed, then stained with antibody for CD8+ T-cell markers. T-cells were then 
permeabilized, and stained for intracellular IFN-γ. All cells were then observed by flow 
cytometry, with appropriate controls used to detect background levels of IFN-γ (Fig 3.5A). 
TIL alone with no melanoma cells, as well as melanoma cells done with no TIL were used 
as controls. The results revealed that the TIL co-cultured with WT-A2 and ∆Y-A2 HLA-A2 
transduced cells produced more IFN-γ after BRAF inhibitor treatment. However, TIL co-
cultured with ∆T-A2 and ∆S-A2 transduced cell lines showed no significant increases in 
IFN-γ secretion consistent with the flow cytometry results. These results show that the 
inhibition of oncogenic BRAF can have a direct effect on TIL IFN-γ production. 
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We also repeated the experiment using HLA-A2 transduced WM793 cells, except 
the cells were incubated with 50nM of MART-1 peptide for the final hour of the 3 hour 
BRAFi treatment. Similar to the results with Mel888 cells, the results from these 
experiments correlated well with our MHC-I flow cytometry results. As expected, the T-
cells produced more IFN-γ in response to exposure to the cell lines transduced with WT-A2 
and ∆Y-A2. By contrast, notable were the results of the ∆T-A2 and ∆S-A2 cell lines, which 
elicited only slight decreases or no change in the frequency of IFN-γ  positive CD8 cells in 
comparison to those cells co-cultured with untreated cells (Fig 3.5B).   
In order to understand how cytokine secretion by the MART-1 T-cells related to 
antigen presentation, T2 cells were pulsed with increasing concentrations of MART-1 
peptide and assessed IFN-γ secretion elicited by T-cells was measured. In parallel, the same 
MART-1 specific TILs were incubated with Mel888 cells before and after BRAF inhibitor 
treatment. An IFN-γ ELISA was performed with the transduced Mel888 cells after a 3 hour 
treatment with BRAFi or with DMSO; each cell line was co-cultured with MART-1 TIL for 
8 hours, and we measured the levels of IFN-γ secreted into the supernatant. The results in 
Figure 3.5C show the level of IFN-γ released by the TIL incubated with transduced Mel888 
cells in comparison to the level of IFN-γ released in response to peptide-pulsed T2 cells.  
The top panel shows that the WT-A2 cell line had what would be an equivalent of a 4-fold 
increase of peptide on the cell surface, following BRAF treatment in comparison to the T2 
peptide-pulsed cells. The ∆Y-A2 cell line displayed what would equate to a 6-fold increase 
of peptide on the cell surface when compared to T2 cells pulsed with peptide.  These results 
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demonstrate how the upregulation of MHC-I surface expression has on the cell surface can 
affect T-cell recognition.  
We also measured the level of IFN-γ secreted into the supernatant by MART-1 
specific TILS co-cultured with WM793 cells pulsed with 50nM of MART-1 peptide. (Fig 
3.5D). The results were consistent with our previous experiment: MART-1 TILs co-cultured 
with WT-A2 and ∆Y-A2 expressing cells showed increases of IFN-γ; following BRAFi 
treatment. By contrast, TILs co-cultured with ∆T-A2 and ∆S-A2 showed no change in IFN-γ 
released. These results confirm that the MHC-I upregulation by the MAPK pathway plays a 
potentially significant role in immunological recognition of tumor cells by T-cells.  Our 
results also point to serine-335 as the site that could be the key to this mechanism. 
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Figure 3.5 BRAF inhibitor treatment of BRAF mutant cell lines increases subsequent 
T-cell recognition and IFN-γ secretion. (A)Frequency of IFN-γ expressing CD8+ T-cells 
following co-culture with MART-1 expressing Mel888 cells transduced to express WT 
HLA-A2 or cytoplasmic tail variants of HLA-A2: ∆T, ∆Y, and ∆S. Cells were treated with 
BRAF inhibitor for 3 hours, washed, and then co-cultured for 8 hours with MART-1 specific 
T-cells. Frequency of IFN-γ positive T-cells are shown for each cell line with or without 
inhibitor treatment. (B) Frequency of IFN-γ cytokine-expressing CD8+ T-cells following co-
culture with WM793 cells pulsed with 50nM of MART-1 peptide.  Cells were treated with 
BRAF inhibitor for 3 hours including MART-1 peptide for the final hour, washed, and then 
co-cultured for 8 hours with T-cells. (C) Results of ELISA assay measuring IFN-γ released 
into the supernatant by MART-1 specific T-cells after 8 hour co-culture with HLA-A2 
transduced Mel888 cells, treated with or without BRAF inhibitor for 3 hours. In parallel, T2-
cells pulsed with a titrated amounts of MART-1 peptide were assessed as stimulator cells for 
the same CD8+ T-cells.(D) MART-1 peptide pulsed HLA-A2 transduced WM793 cells 
treated with BRAF inhibitor or DMSO (vehicle) for 3 hours. All experiments were repeated 
at least three times with similar results. (* indicates  p < 0.05; NS: not significant). 
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Figure 3.5   
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3.6 Assessing the steady-state rate of internalization of MHC-I in BRAF WT and 
BRAF mutant cell lines. 
In order to better understand the mechanism behind the oncogenic regulation of 
MHC-I surface expression; we next initiated a series of confocal microscopy experiments. 
We first compared the steady state internalization rates of MHC-I in the BRAF mutant cell 
line Mel888 and the BRAF WT cell line HS294T.  Cells were first seeded and plated onto 
Ibidi 12-well chambers on microscope glass slides. Cells were put on ice to stop 
internalization, and stained with AF488–labeled with W6/32 antibody to stain for total 
MHC-I. Cells were incubated at 37 degrees for various time points, after which they were 
taken out, fixed, and surface stained using goat anti mouse antibody conjugated with AF555. 
Cells were then observed by confocal microscopy.  
The result for the HS294T cells shows that MHC-I surface expression does not 
significantly change from baseline to 180 minutes. In addition the level of MHC-I 
internalized also remains close to baseline levels after 180 minutes (Fig 3.6A).  By contrast, 
Mel888 cells showed significant internalization of MHC-I over the same time period (Fig. 
3.6B). These results reveal that there is a more rapid constitutive rate of MHC-I 
internalization in Mel888 cells compared to HS294T cells. These results are consistent with 
our flow cytometry studies (Fig 3.1C) and support the notion that oncogenic BRAF is 
driving the enhanced internalization observed.  
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Figure 3.6 The steady-state rate of internalization of MHC-I in BRAF WT and BRAF 
mutant cell lines. (A) Confocal microscopy analysis of the BRAF WT cell line HS294T. 
The red fluorescence represents surface MHC-I, green is total MHC-I, and the bottom panel 
shows a merged image (yellow). (B) Quantification of the average pixel fluorescence per 
cell of surface MHC-I (red) and internalized MHC-I (green in merged image). (C) Confocal 
microscopy analysis of the BRAF mutant cell line Mel888.  (D) Quantification of the 
average pixel fluorescence per cell of surface MHC-I (yellow in merged image) and 
internalized MHC-I (green in merged image). All experiments were repeated twice with 
similar results. Imaging done by Dr. Zeming Chen 
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Figure 3.6  
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3.7 BRAF inhibitor slows constitutive MHC-I internalization in a cytoplasmic tail 
dependent matter.   
After determining that MHC-I is rapidly internalized in BRAF mutant cell lines, we 
next wanted to know if MAP kinase pathway inhibition affected this internalization. 
Abrogation of MHC-I internalization may lead to the increase in cell surface MHC-I that we 
have consistently observed after BRAFi treatment.  If this is the mechanism, we would 
expect that following removal of the BRAFi, MHC-I should begin to internalize again and 
return to baseline surface levels. To test this prediction, we treated Mel888 cells with BRAF 
inhibitor for 3 hours and measured total MHC-I at different time points, following drug 
removal.  As expected, MHC-I surface expression increased by flow cytometry following 
inhibitor BRAF treatment in Mel888 cells but not WT BRAF-expressing MeWo cells (Fig 
3.7A).  However, following drug removal, MHC-I surface levels in Mel888 cells 
progressively decreased until falling back to baseline levels by 3 hours. These results 
support a model in which BRAF inhibitor treatment halts or slows MHC-I internalization in 
BRAF mutant cells, which leads to an increase in MHC-I on the cell surface. Since the WT 
BRAF-expressing cell line, MeWo showed no change in MHC-I following BRAFi treatment 
and after removal of drug, this supports the idea that oncogenic BRAF is driving the rapid 
and constitutive internalization of MHC-I. 
We next wanted to determine how the MHC-I cytoplasmic tail affected MHC-I 
internalization in the Mel888 cell line. A similar experiment to the one described above was 
performed, except that we monitored HLA-A2 surface expression in Mel888 cells 
transduced with WT-A2 and tailless A2.  WT HLA-A2 demonstrated similar dynamics of 
surface expression changes as total MHC-I in response to BRAFi addition and removal (Fig 
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3.7B). However, tailless HLA-A2 showed no change in MHC-I surface expression 
following drug addition and removal. These results show that constitutive internalization of 
MHC-I in Mel888 is not only dependent upon oncogenic BRAF, but also the MHC-I 
cytoplasmic tail. 
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Figure 3.7 BRAF inhibitor slows constitutive MHC-I internalization in BRAF mutant 
melanoma cell line.  (A) Dynamics of total MHC-I surface expression in Mel888 cells 
following addition and removal of the BRAF inhibitor. BRAF-WT expressing MeWo cells 
were used as a negative control. Cells were observed by flow cytometry at different time 
points, following staining with W6/32 mAb. (B) Dynamics of HLA-A2 surface expression 
following addition and removal of BRAF inhibitor in Mel888 cells transduced to express 
WT HLA-A2 or tailless HLA-A2. Cells were observed by flow cytometry at different time 
points following staining with mAb BB7.2. All experiments were repeated at least twice 
with similar results. 
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Figure 3.7  
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Figure 3.8 MHC-I internalization in BRAF mutant cells is reduced after BRAF 
inhibitor treatment.  
 In our next set of experiments, we sought to determine the intracellular distribution 
of MHC-I following MAPK pathway inhibition. The BRAF mutant cell line WM793 was 
treated with either DMSO or the BRAFi (dabrafenib) for 2 hours, after which time the 
surface MHC-I was labeled with anti-mouse conjugated with W6/32 and the cells were then 
placed at 37 degrees for another a further 90 minutes in the presence of  DMSO or BRAFi. 
After 90 minutes, the cells were stained for remaining surface MHC-I using goat anti-mouse 
IgG conjugated to W6/32. The results revealed that the DMSO-treated control cells had less 
MHC-I remaining on the cell surface after 90 minutes, compared with the BRAFi-treated 
cells, which demonstrated significantly brighter MHC-I surface expression after the same 
incubation time (Fig. 3.8A). As shown in the bottom panel of Figure 3.8, a merged image of 
total MHC-I (green) and the surface MHC-I (red) is displayed as a yellow color. The 
DMSO-treated cell line has less surface class I and more internalized MHC-I. By contrast, 
the BRAF-treated cell line has less internalized MHC-I and more surface class I on the cell 
surface because of the BRAF treatment.  
To quantify the changes in intracellular MHC-I distribution, the program Image J 
was used to analyze cells and obtain the average fluorescence pixel intensity of each color 
per cell (Fig. 3.8B). The results of the quantification show significant differences in MHC-I 
intracellular distribution following BRAFi treatment: more MHC-I surface expression was 
seen in BRAFi-treated cells in comparison to the DMSO-treated cells. These results are 
consistent with our flow cytometry results and support the notion that MHC-I surface 
expression can be regulated by BRAF in melanoma cells. 
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Figure 3.8 MHC-I internalization in BRAF mutant cells is reduced after BRAF 
inhibitor treatment.  (A) BRAF mutant cell line WM793 treated with control DMSO after 
a total of 3 hours, surface MHC-I (red), internalized MHC-I (green) and a merged image 
(yellow) indicates co-localization of green and red.  (B) Quantification of the average pixel 
fluorescence per cell of surface MHC-I and internalized MHC-I.  The white arrows indicate 
internalized class I. All experiments were repeated at least twice with similar results. 
Imaging done by Dr. Zeming Chen 
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Figure 3.8  
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4.1 Summary 
The major aim of this thesis was to first determine the effect of MAPK pathway 
inhibitors on MHC-I surface expression. We also sought to determine the role of the MHC-I 
cytoplasmic tail in the MAPK pathway modulation of MHC-I surface expression and to 
assess any differences in T-cell recognition after MAPK inhibition. We also attempted to 
determine the mechanism behind the MAPK pathway regulation of MHC-I surface 
expression through observing the steady-state internalization of MHC-I in melanoma cells 
and the effects of MAPK pathway inhibitors on internalization. To address these questions, 
we compared BRAF mutant cell lines and BRAF WT cell lines, and also used BRAF mutant 
melanoma cell lines transduced to express WT-A2 and three cytoplasmic tail mutants.  Our 
study reveals that the oncogenic MAP kinase pathway can modulate MHC-I surface 
expression in BRAF mutant cell lines in a cytoplasmic tail-dependent manner. 
We found that MAPK-inhibitor induced modulation of MHC-I surface expression 
occurs in BRAF mutant cell lines but does not take place in BRAF WT melanoma cells. Our 
studies not only show that the oncogenic MAPK pathway modulates MHC-I surface 
expression in a cytoplasmic tail dependent matter,  but also appears to be controlled by the 
highly conserved serine-335 residue encoded by exon 7 of the MHC-I gene. We showed that 
constitutive activation of the MAP kinase pathway in BRAF mutant cell lines leads to an 
internalization of MHC-I that can be reversed by inhibition of the pathway.  The increase in 
surface MHC- I led to a subsequent increase in T-cell recognition and cytokine release. Our 
results point to a possible mechanism of immune system evasion by which melanoma cells 
with activating BRAF mutations downregulate MHC- I on the cell surface in order to escape 
immune recognition and killing.  
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4.2 Early effects of MAPK pathway inhibition in melanoma 
We have shown that upregulation of MHC-I surface expression takes place following 
MAP kinase pathway inhibition (Figures 3.4 and 3.5); these results are supported by 
previous reports where MHC-I was also shown to increase on the cell surface in other 
melanoma cell lines following MAPK pathway inhibition [67,68]. However, our results 
differ significantly with respect to the time points that were analyzed. Both of these reports 
demonstrated MHC-I transcriptional upregulation at 24 to 72 hours following drug 
treatment, whereas we analyzed much earlier time points (30 minutes to 3 hours) following 
drug treatment. We showed that MHC-I upregulation happens much more quickly than 
previously reported, and therefore likely occurs independent of transcription. The changes 
observed at these early time points suggested a post-translational mechanism, which we 
explored further using HLA-A2 containing mutated phosphorylation sites. Although we also 
acknowledge that BRAF inhibition induces profound changes in gene expression that can 
lead to many downstream changes within the tumor cells, our analysis was performed at 
time points that precluded these changes. Previous analysis showed that the BRAF inhibitor 
can produce rapidly induced changes that affect more than just MHC-I.  For example, a 
study by Khalili et al. [19] showed that transduction of melanocytes cells with the BRAF 
(V600E)
 gene induced the transcription of IL-1 alpha and beta.  When the BRAF inhibitor 
vemurafenib was used on BRAF mutant cell lines, the level of interleukin 1 alpha and beta 
mRNA sharply declined in these cells within 3 to 4 hours. However, changes in protein 
expression were not observed until later time points.  
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4.3 The role of the cytoplasmic tail in melanoma MHC-I surface expression 
The mechanism behind the regulation of MHC-I by the MAP kinase pathway has 
remained understudied and the mechanisms poorly understood. In this study, we attempted 
to shed more light on this mechanism by looking into the internalization of MHC-I in the 
context of a constitutively activated oncogenic MAP kinase pathway. We showed that the 
steady-state internalization of MHC-I took place very rapidly in BRAF mutant melanoma 
cell lines. Decreases in MHC-I cell surface expression could be detected as early as 30 
minutes (Figure 3.5). This constitutive internalization of MHC-I was slowed in melanoma 
cells with the BRAFi, but in cells that do not harbor the BRAF mutation, the BRAFi had 
little to no effect. Our findings thus are consistent with a model whereby the rapid 
internalization of MHC-I is driven by the oncogenic MAP kinase signaling pathway. It 
would be of interest to determine the half-life of MHC-I molecules in BRAF mutant cells 
before and after BRAFi treatment. If MHC-I protein half-life is stabilized after inhibitor 
treatment in melanoma cells, this would be consistent with our results. Alternatively, BRAFi 
may not be affecting MHC-I molecular stability, but simply inducing an intracellular 
redistribution of MHC-I. 
We also showed that the internalization of MHC-I molecules is linked to the MHC-I 
cytoplasmic tail. More specifically, the modulation appears to be is linked to the highly 
conserved serine-335 encoded by exon 7 of the MHC-I gene. The MHC-I cytoplasmic tail 
has already been shown to be involved in endosomal trafficking of MHC-I in dendritic cells. 
In contrast to our results, the tyrosine-320  encoded by exon 6 is responsible for this 
phenomenon [52]. However, since the MAP kinase pathway is a serine-threonine protein 
kinase signaling cascade [74], it makes sense that the serine residue would be the target of 
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phosphorylation in these cells and not the tyrosine. If the cytoplasmic serine phosphorylation 
site regulates MHC-I surface expression in melanoma cells with BRAF mutations, this raises 
the possibility that other oncogenic signaling pathways in other tumors may operate work in 
a similar matter. For example, oncogenic KRAS mutations are very common in pancreatic 
cancer, and constitutive MAPK activation is a hallmark of many other tumor types [15]. 
Regardless, we are the first to show that the serine phosphorylation site on the MHC-I 
cytoplasmic tail regulates MHC-I surface expression in tumor cells with constitutive MAPK 
pathway activation. A working model depicting the potential mechanism behind MHC-I 
modulation by oncogenic BRAF in melanoma cells is shown in Figure 4.1. 
 
    
 
77 
 
 
Figure 4.1 Potential mechanism for the modulation of MHC-I surface expression in BRAF 
mutant cell lines. Rapid internalization of newly produced MHC-I molecules may be linked to the 
phosphorylation of the highly conserved serine located on the MHC-I cytoplasmic tail. MHC-I may 
be degraded in lysosomes post internalization or held in early/late endosomes in BRAF mutant cell 
lines. 
 
 
 
 
 
 
 
Potential mechanism for the modulation of  
MHC-I surface expression  
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4.4 The role of BRAF inhibition in CD8+ T-cell recognition  
MHC-I molecules play a critical role in CTL-mediated killing of tumor cells. One of 
the overall goals of our studies was to connect our observations of MHC-I expression and 
discoveries to potential improvements in CTL recognition and killing. The potential impact 
of MAPK pathway inhibition in T-cell recognition of melanoma tumors may have the most 
important implications for immunotherapy-based cancer treatment. Our results show that 
melanoma cells transduced with HLA-A2 point mutants behaved very differently from one 
another in terms of inducing T cell recognition; for example, only the WT-A2 and ∆Y-A2 
transduced cell lines were able to induce better T-cell recognition after BRAFi treatment. In 
these experiments, we showed that CTL-mediated killing can be affected even at early time 
points following BRAFi treatment, points and even seemingly small shifts in MHC-I 
expression can have significant effects on cytokine production. We observed significant 
changes in the amount of IFN gamma released after BRAFi treatment, but it would also be 
beneficial to look at the difference in the percentage of tumor cells killed following inhibitor 
treatment.  In both the ∆T- A2 and ∆S-A2 cell lines, HLA-A2 upregulation does not take 
place after treatment with inhibitors at early time points Figure 3.4, thus implicating the 
cytoplasmic tail serine-335 residue in the oncogenic pathway MAPK pathway modulation of 
MHC-I. It is possible that in all BRAF mutant cell lines, the MHC-I molecules are being 
phosphorylated at this highly conserved serine, which then triggers internalization [75]. 
There is still a lot of information to discover about the role of the MHC-I cytoplasmic in 
peptide presentation and anti-tumor immunity. In DCs the removal of exon 7 encoded amino 
acids from the MHC-I cytoplasmic tail, which contains the serine-335, contributed to longer 
half-life of MHC-I, better T-cell recognition, and anti-tumor immunity [57].  However, Tyr-
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320 appears to also be very important for MHC-I trafficking in APCs, suggesting that DCs 
and tumor cells may very well behave quite differently from one another in this regard. 
Serine-335 may be required in tumor cells for oncogenic induced MHC-I downregulation, 
but in DCs tyrosine-320 phosphorylation may be more important for a different aspect of 
antigen presentation. These differences show that more studies need to be conducted to 
better understand how the MHC-I cytoplasmic tail and MAPK signaling functions in 
different cell types, which could help further the development of treatments for cancer 
patients.  
4.5 Pharmacological Implications 
There are still many questions left to answer regarding confirming serine335 as a 
potential phosphorylation site, including identifying the exact kinase that may phosphorylate 
the serine residue, and whether these findings can be applied to other types of cancers with 
oncogenic mutations. The first step to better understand the role of the MHC-I cytoplasmic 
tail, is to determine the molecules involved in its function. For example, the phosphatases 
and kinases that use the MHC-I cytoplasmic tail as a substrate have yet to be identified.  For 
our study, if the serine kinase that phosphorylates serine-335 in BRAF mutant cells could be 
identified and targeted with a highly specific kinase inhibitor it would be interesting to see if 
we would observe the same effects as we saw with the BRAF inhibitor. In addition to Tyr 
320 playing a role in trafficking through endosomal compartments of DCs, and Serine (Ser-
335) playing a role in antigen presentation in tumor cells,  there is also a highly conserved 
ubiquitination site Lys-316 [76] that may be important for immune system recognition as 
well. Identifying the kinases and phosphatases for which the MHC-I cytoplasmic tail is a 
substrate could have significant implications for targeted therapy of cancer. If kinase 
    
 
80 
 
inhibitors specific for the serine or tyrosine phosphorylation sites could be discovered they 
could be tailored to be used in not just in melanoma treatment but also other types of cancers 
that have mutations in oncogenic signaling pathways that affect MHC-I expression. Our 
results suggest that it is possible that the oncogene-targeted treatment could be combined 
with immunotherapy used to increase T-cell recognition, slow tumor growth, and prevent 
metastasis in many types of cancers.  
 4.6 Future Directions 
Perhaps one of the most significant takeaways from this study is the potential 
implications that MHC-I modulation by the MAP kinase pathway may have for antigen 
presentation. Peptide elutions from tumor cells have been used to discover new melanoma 
antigens in the past and to create vaccines [77,78,79].  It would therefore be interesting to 
examine the peptides eluted from the cell surface of the melanoma cells before and after 
MAPK inhibition. Comparisons can be made about the total number of peptides eluted from 
each, the diversity of the peptides, and potentially their function. It would also be interesting 
to study the differences in HLA-A2 restricted peptides eluted from cell lines expressing WT 
versus tailless HLA-A2. If differences are detected in antigen presentation, T-cells specific 
for those antigens could and be possibly exploited as new melanoma target antigens that 
would be preferentially expressed in the context of BRAFi treatment. 
Further confocal microscopy studies will be required to answer all of the mechanistic 
questions this study has raised. We determined that MHC-I is indeed stabilized on the 
surface of melanoma cells following MAPK pathway inhibition but there are still more 
questions to be answered. For example, which intracellular what compartments do the 
MHC-I molecules localize to?  Are they being degraded immediately, or simply being 
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sequestered within endocytic compartments? Confocal microscopy experiments that label 
the surface MHC-I molecules and chase them into the cell, along with co-staining of 
intracellular compartments such as early or late endosomes or lysosomes will have to be 
done to address these questions. It will also be interesting to characterize whether any 
differences are seen between trafficking the cytoplasmic tail and co-localization of  the 
cytoplasmic tail mutants of HLA-A2. 
Combination treatments involving inhibitors with other immunotherapies are 
currently being tested in the clinic [80,81]. Several studies, including this one, have 
suggested that oncogene targeted therapies and immunotherapies may show synergy [37]. 
Some new drugs drawing a lot of attention lately are Ipilimumab, an antibody specific for 
the negative regulator of  T- cells CTLA- 4 [82] and molecules such as check point blockade 
antibodies targeting PD-L1 and PD-1 [83]. Alternative signaling pathways closely related to 
the MAPK pathway may also be strong candidates for combination therapy, such as the 
PTEN/AKT inhibitors [84]. There are many possible drug combinations to be tested and it 
will be interesting to determine how MHC-I surface expression and antigen presentation are 
affected by these combinations, and more importantly what the implications are for CTL-
mediated killing of tumor cells.                                            
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